Loading...
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally,...
Na minha lista:
| Udgivet i: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7563142/ https://ncbi.nlm.nih.gov/pubmed/32882980 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12092480 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|